Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Diabetic Macular Edema
Biotech
Merck has clear vision to eye disease assets with $3B EyeBio buy
Merck & Co. is focusing in on eye diseases with the $3 billion acquisition of ophthalmology-focused Eyebiotech.
Annalee Armstrong
May 29, 2024 8:32am
Rezolute’s oral Eylea rival hits phase 2 goal, sending stock up
May 22, 2024 7:15am
Oxurion fails phase 2 eye disease trial, plans bankruptcy filing
Nov 20, 2023 8:30am
Kodiak resurrects eye drug after ph. 3 data renew approval plans
Nov 6, 2023 8:40am
'Unexpected' cataracts in ph. 3 end Kodiak's hopes for eye drug
Jul 24, 2023 8:58am
Unity preps for Eylea battle following extended midstage test
Apr 24, 2023 10:25am
